It’s where it is because insiders and major shareholders are the ones that have bought the stock. Follow the money
Three major key events in coming days:
- First is the completion of the most important cohort and complete primary objectives on dosing and pharmacokinetics and we now sit in line with our 100 million dollar peers
- Second is the results of Boehringer which confirm that we will work in humans to treat Kidney fibrosis and point to the direction that we will be more effective in treatment than Boehringer and DXB as studies have already proven that inhibiting channels 3 and 6 is more effective in treatment than 6 alone. Hence becoming a Takeover target
- Third AGN results but due to the cross reactivity of GLN2b and GLN2A receptor on Glutamate which inhibits both death and protection of neuron's in humans not in animals then its 12 hour half life may be its downfall. However if it passes this issue then it proves inhibiting calcium influx protects from brain injury and that’s exactly what NYR does at the ion channel level
3 key events in coming days and at a 50 million market cap it still has a lot to move for it to be just in line with its peers just on brain injury. Boehringer results are transformative for the company
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)